These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 15363993)

  • 21. Effect of aspirin on platelet desaggregation induced by SR121566, a potent GP-IIb/IIIa antagonist.
    Savi P; Bernat A; Lalé A; Roque C; Zamboni G; Herbert JM
    Platelets; 2000 Feb; 11(1):43-8. PubMed ID: 10938881
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of a synthetic peptide corresponding to residues 313 to 320 of the alphaIIb subunit of the human platelet integrin alphaIIbbeta3 on carotid artery thrombosis in rabbits.
    Papamichael ND; Stathopoulou EM; Roussa VD; Tsironis LD; Kotsia AP; Stanica RM; Moussis V; Tsikaris V; Katsouras CS; Tselepis AD; Michalis LK
    J Pharmacol Exp Ther; 2009 May; 329(2):634-40. PubMed ID: 19244095
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blockade of glycoprotein IIb/IIIa mediates the antithrombotic activity of butanol fraction of Actinostemma lobatum Maxim.
    Kim KH; Lee HJ; Lee JH; Jang YS; Kim DK; Shim BS; Cho KH; Ko SG; Ahn KS; Kim SH
    J Ethnopharmacol; 2008 Mar; 116(3):431-8. PubMed ID: 18243609
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Görög Thrombosis Test: a global in-vitro test of platelet function and thrombolysis.
    Yamamoto J; Yamashita T; Ikarugi H; Taka T; Hashimoto M; Ishii H; Watanabe S; Kovacs IB
    Blood Coagul Fibrinolysis; 2003 Jan; 14(1):31-9. PubMed ID: 12544726
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiplatelet and antithrombotic activity of RWJ-53308, a novel orally active glycoprotein IIb/IIIa antagonist.
    Damiano BP; Mitchell JA; Giardino E; Corcoran T; Haertlein BJ; de Garavilla L; Kauffman JA; Hoekstra WJ; Maryanoff BE; Andrade-Gordon P
    Thromb Res; 2001 Oct; 104(2):113-26. PubMed ID: 11672755
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the antithrombotic effects of FK633, GPIIb/IIIa antagonist, and aspirin in a guinea pig thrombosis model.
    Aoki T; Cox D; Senzaki K; Seki J; Tanaka A; Takasugi H; Motoyama Y
    Thromb Res; 1998 Feb; 89(3):129-36. PubMed ID: 9622041
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antithrombotic effects of TAK-029, a novel GPIIb/IIIa antagonist, in guinea pigs: comparative studies with ticlopidine, clopidogrel, aspirin, prostaglandin E1 and argatroban.
    Kawamura M; Imura Y; Moriya N; Kita S; Fukushi H; Sugihara H; Nishikawa K; Terashita Z
    J Pharmacol Exp Ther; 1996 Apr; 277(1):502-10. PubMed ID: 8613960
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In-vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists and thrombolytics on platelet/fibrin-mediated clot dynamics in human whole blood using thrombelastography.
    Mousa SA
    Blood Coagul Fibrinolysis; 2007 Jan; 18(1):55-60. PubMed ID: 17179828
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The novel and orally active thrombin receptor antagonist E5555 (Atopaxar) inhibits arterial thrombosis without affecting bleeding time in guinea pigs.
    Kogushi M; Matsuoka T; Kawata T; Kuramochi H; Kawaguchi S; Murakami K; Hiyoshi H; Suzuki S; Kawahara T; Kajiwara A; Hishinuma I
    Eur J Pharmacol; 2011 Apr; 657(1-3):131-7. PubMed ID: 21300059
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination of a direct thrombin inhibitor and a platelet glycoprotein IIb/IIIa blocking peptide facilitates and maintains reperfusion of platelet-rich thrombus with alteplase.
    Sabatine MS; Tu TM; Jang IK
    J Thromb Thrombolysis; 2000 Oct; 10(2):189-96. PubMed ID: 11005941
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nonpeptide factor Xa inhibitors III: effects of DPC423, an orally-active pyrazole antithrombotic agent, on arterial thrombosis in rabbits.
    Wong PC; Crain EJ; Watson CA; Zaspel AM; Wright MR; Lam PY; Pinto DJ; Wexler RR; Knabb RM
    J Pharmacol Exp Ther; 2002 Dec; 303(3):993-1000. PubMed ID: 12438519
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiplatelet and antithrombotic effects of orbofiban, a new orally active GPIIb/IIIa antagonist, in guinea pigs.
    Ogawa T; Sugidachi A; Naganuma H; Asai F
    Thromb Res; 2000 Mar; 97(5):307-15. PubMed ID: 10709906
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiplatelet and antithrombotic activity of SL65.0472, a mixed 5-HT1B/5-HT2A receptor antagonist.
    Berry CN; Lorrain J; Lochot S; Delahaye M; Lalé A; Savi P; Lechaire I; Ferrari P; Bernat A; Schaeffer P; Janiak P; Duval N; Grosset A; Herbert JM; O'Connor SE
    Thromb Haemost; 2001 Mar; 85(3):521-8. PubMed ID: 11307825
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The in-vitro effect of tirofiban, glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.
    Ciborowski M; Tomasiak M; Rusak T; Winnicka K; Dobrzycki S
    Blood Coagul Fibrinolysis; 2008 Sep; 19(6):557-67. PubMed ID: 18685439
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of thrombin inhibitors and a glycoprotein IIb/IIIa receptor antagonist in an ex vivo human experimental thrombosis model.
    Zokai K; Piazolo L; Harenberg J
    Semin Thromb Hemost; 2001 Oct; 27(5):531-6. PubMed ID: 11668424
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A defined peptide that inhibits the formation of the glycoprotein IIb and IIIa complex.
    Chiang TM; Zhu J
    Thromb Res; 2005; 115(6):503-8. PubMed ID: 15792682
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of carboxypeptidase U (TAFIa) activity improves rt-PA induced thrombolysis in a dog model of coronary artery thrombosis.
    Björkman JA; Abrahamsson TI; Nerme VK; Mattsson CJ
    Thromb Res; 2005; 116(6):519-24. PubMed ID: 16181987
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of PAI-039 [{1-benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}(oxo)acetic acid], a novel plasminogen activator inhibitor-1 inhibitor, in a canine model of coronary artery thrombosis.
    Hennan JK; Elokdah H; Leal M; Ji A; Friedrichs GS; Morgan GA; Swillo RE; Antrilli TM; Hreha A; Crandall DL
    J Pharmacol Exp Ther; 2005 Aug; 314(2):710-6. PubMed ID: 15860572
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic time window of tacrolimus (FK506) in a nonhuman primate stroke model: comparison with tissue plasminogen activator.
    Furuichi Y; Maeda M; Matsuoka N; Mutoh S; Yanagihara T
    Exp Neurol; 2007 Mar; 204(1):138-46. PubMed ID: 17169359
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sildenafil improves coronary artery patency in a canine model of platelet-mediated cyclic coronary occlusion after thrombolysis.
    Lewis GD; Witzke C; Colon-Hernandez P; Guerrero JL; Bloch KD; Semigran MJ
    J Am Coll Cardiol; 2006 Apr; 47(7):1471-7. PubMed ID: 16580539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.